Company Overview - Yunnan Baiyao was established in 1902 and is recognized as a leading innovative representative of traditional Chinese medicine [2] - The company has been listed on the Shenzhen Stock Exchange since 1993 and has consistently provided dividends to shareholders for 30 years [2] - Yunnan Baiyao aims to integrate traditional Chinese medicine into modern life and continuously innovates its product offerings [2] R&D Investment - The company has increased its R&D investment, with over 1,200 R&D personnel and an investment of 343 million CNY in 2022, accounting for 2.68% of industrial sales revenue [3] - R&D expenses rose from 174 million CNY in 2019 to 337 million CNY in 2022 [3] Traditional Chinese Medicine Innovation - Yunnan Baiyao has 247 traditional Chinese medicine products and 354 related approvals, including 43 exclusive products and 53 exclusive approvals [4] - The company is actively involved in the secondary development of traditional medicine products and has initiated several key research projects, including treatments for COVID-19 and other health conditions [4] Market Value Management - The company places high importance on market value management by enhancing governance structures, improving information disclosure, and establishing a stable dividend mechanism to increase investor returns [6]

云南白药集团股份有限公司 投资者调研会议记录表 编号：15-2306-01 | --- | --- | --- | |--------------------|---------------|-------------| | | □特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | ☑现场参观 | □一对一沟通 | ☑其他（走进上市公司） 参与单位名称及人员 "走进成分股公司·云南白药站"走进上市公司活动机构投资 者 65 人 姓名 时间 2023 年 6 月 9 日 地点 集团"白药空间"大楼 上市公司接待人员 董事-谢云山，董事会秘书-钱映辉，证券事务代表-赵雁，项目 管理-李孟珏，投资者关系管理-桂博翔、杨可欣 投资者关系活动主要 内容介绍 了解公司生产经营情况等相关问题。 附件清单 会议记录 日期 2023 年 6 月 9 日星期五 1 / 1 ...

云南白药集团股份有限公司 投资者调研会议记录表 编号：13-2305-01 | --- | --- | --- | |--------------------|--------------------------|------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系活动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | 一对一沟通 | | | 其他（电话会议） | | | | 兴业证券股份有限公司 | -董晓洁 | | | 安信证券投资有限公司 | -王紫嫣 | | | 工银瑞信基金管理有限公司 | -彭小溪 | | | 创金合信基金管理有限公司 | -陈建军 | | | 中国银河证券股份有限公司 | -朱艺泓 | | | 平安证券股份有限公司 | -邢洁 | | 参与单位名称及人员 | 益民基金管理有限公司 | -高喜阳 | | 姓名 | 合众资产管理股份有限公司 | -郭子煜 | | | 中海基金管理有限公司 | -彭天阳 | | | 建信信托有限责任公司 | -孙海梦 | | | 中银国际证券股份有限公司 | -刘航 | | ...

云南白药集团股份有限公司 投资者调研会议记录 时间：2023 年 5 月 18 日 地点：集团总部办公大楼 召开方式：现场调研 投资者：德邦证券-张俊，中银国际证券-薛源 参加人员：项目管理-李孟珏，投资者关系管理-杨可欣 会议内容 1、口腔护理品牌"齿说"在 2022 年有何经营亮点？ 答：口腔智护业务单元致力于成为口腔智护方案提供商，报告期 内公司上线"齿说"（ToothTalk）口腔科学专研品牌，产品包括： 智能电动牙刷、冲牙器、个性化刷头、漱口水、凝胶、口喷等。齿说 品牌通过消费者洞察、产品开发、产品上市、产品推广四位一体快速 迭代打造爆品，齿说红白口喷增速迅猛，短期内该单品销售收入突破 千万，问鼎抖音平台多项榜单第一。齿说品牌通过"i 看呀"小程序 连接 C 端用户，精准进行私域运营。"i 看呀"定位为口腔咨询服务 平台，为用户提供更便利的线上口腔科普、咨询及预约治疗服务。 2、请介绍一下公司 2023 年一季度的财务情况。 答：2023 年一季度，公司实现营业收入 105.13 亿元，同比增长 11.49%；经营活动产生的现金流量净额 7.34 亿，同比增长 530.84%； 归属于上市公司股东的 ...

云南白药集团股份有限公司 投资者调研会议记录表 编号：14-2305-02 | --- | --- | --- | |--------------------|-------------------|------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | 路演活动 | | | 现场参观 | 一对一沟通 | | | 其他（电话会议） | | | 参与单位名称及人员 | 德邦证券-张俊 | | | 姓名 | 中银国际证券-薛源 | | 时间 2023 年 5 月 18 日 地点 集团总部办公大楼 上市公司接待人员 项目管理-李孟珏 投资者关系管理-杨可欣 投资者关系活动主要 内容介绍 了解公司生产经营情况。 附件清单 会议记录 日期 2023 年 5 月 18 日星期四 1 / 1 ...

云南白药集团股份有限公司 投资者调研会议记录 时间：2023 年 5 月 17 日 地点：集团总部办公大楼 召开方式：现场调研 投资者：兴业证券股份有限公司-董晓洁，安信证券投资有限公 司-王紫嫣，工银瑞信基金管理有限公司-彭小溪，创金合信基金管理 有限公司-陈建军，中国银河证券股份有限公司-朱艺泓，平安证券股 份有限公司-邢洁，益民基金管理有限公司-高喜阳，合众资产管理股 份有限公司-郭子煜，中海基金管理有限公司-彭天阳，建信信托有限 责任公司-孙海梦，中银国际证券股份有限公司-刘航，建信理财有限 责任公司-郑蕾蕾，诺德基金管理有限公司-朱明睿，OrbiMed-Claire 参加人员：董事会秘书-钱映辉，证券事务代表-赵雁，投资者关 系管理-杨可欣 会议内容 1、国家鼓励发展中医药，白药在中药领域有哪些布局，以及有 何战略主张？ 答：党和国家高度重视中医药发展，《"十四五"中医药发展规 划》提出建设高水平中医药传承保护与科技创新体系、推动中药产业 高质量发展等促进中医药事业产业发展重点任务。 云南白药始终致力于推动传统中医药融入现代生活，持续深挖传 统医学产品的内生潜力，以产品创新回应现代生活需求，不断为传 ...

股票代码：000538 股票简称：云南白药 公告编号：2023-18 云南白药集团股份有限公司 董 事 会 2023 年 5 月 8 日 1 / 1 关于参加 2022 年度云南辖区上市公司投资者网上集体接待日 暨集体业绩说明会的公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，云南白药集团股份有限公司（以下简 称"公司"）将参加由云南证监局、云南省上市公司协会与深圳市全景网络有 限公司联合举办的"2022 年度云南辖区上市公司投资者网上集体接待日暨集 体业绩说明会"，现将有关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net/），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2023 年 5 月 11 日（周四）10:30 至 12:00。 届时公司部分高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营 状况、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者积极参与。 特此公 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 12,750,996,996.14, representing an increase of 11.49% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 1,517,988,356.56, a significant increase of 66.01% year-on-year[5] - Basic earnings per share increased by 19.72% to CNY 0.85 from CNY 0.71 in the same period last year[5] - Total operating revenue for Q1 2023 reached CNY 10,512,750,996.14, an increase of 11.5% compared to CNY 9,429,539,929.02 in Q1 2022[19] - Net profit for Q1 2023 was CNY 1,515,723,471.89, representing a 67.9% increase from CNY 903,564,058.61 in Q1 2022[21] - The total comprehensive income for Q1 2023 was CNY 1,522,285,067.19, compared to CNY 896,950,266.96 in the same quarter last year[22] Cash Flow - The net cash flow from operating activities reached CNY 733,744,202.46, a remarkable improvement of 530.84% compared to a negative cash flow in the previous year[5] - Cash flow from operating activities generated a net amount of CNY 733,744,202.46, a significant recovery from a net outflow of CNY 170,306,941.45 in Q1 2022[23] - The net cash flow from investment activities was -315,633,657.92 CNY, compared to -816,681,896.54 CNY in the previous period[24] - The net cash flow from financing activities was 131,276,989.91 CNY, compared to 143,000,982.99 CNY in the previous period[24] - The total cash and cash equivalents at the end of the period amounted to 13,590,291,581.13 CNY, up from 13,046,160,012.47 CNY at the beginning of the period[24] - The net increase in cash and cash equivalents for the period was 544,131,568.66 CNY, compared to a decrease of 820,011,084.75 CNY in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 54,732,796,774.46, up 2.65% from the end of the previous year[5] - The total liabilities decreased slightly to CNY 14,680,687,832.48 from CNY 14,793,946,606.95 in the previous year[19] - The total equity attributable to shareholders of the parent company increased to CNY 40,029,274,479.88 from CNY 38,503,673,731.86 year-on-year[19] Investment and Income - Investment income surged by 2,693.58% to CNY 242,399,008.29, primarily due to increased investment income from joint ventures[7] - The company reported a significant decrease in financial expenses by 75.03%, reflecting reduced interest income[7] - Research and development expenses increased to CNY 64,085,946.58, up 22.5% from CNY 52,322,884.63 in the previous year[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 184,251, with the top two shareholders holding a combined 49.27% of the shares[7] - The company plans to distribute a cash dividend of RMB 15.20 per 10 shares (including tax) to all shareholders[13] Corporate Developments - The company appointed Zhao Yingming as Chief Business Officer and Senior Vice President, effective immediately[12] - The company’s board of directors is in the process of electing a new chairman following the resignation of Wang Minghui[11] - The company plans to optimize its organizational structure in 2023 to enhance management capabilities and support strategic goals[15] - The company plans to continue its focus on R&D and market expansion in the pharmaceutical sector[11] Miscellaneous - The company did not undergo an audit for the first quarter report[25] - The company recognized credit impairment losses of 72,455.46 million yuan and asset impairment losses of 57,874.98 million yuan in 2022[14]